Hydrogen-rich water exerts anti-tumor effects comparable to 5-fluorouracil in a colorectal cancer xenograft model
Asgharzadeh Fereshteh, Tarnava Alex, Mostafapour Asma, Khazaei Majid, LeBaron Tyler W · World Journal of Gastrointestinal Oncology · 2022
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
The publication “Hydrogen-rich water exerts anti-tumor effects comparable to 5-fluorouracil in a colorectal cancer xenograft model” is organized in H2HUBB under the research focus hydrogen water cancer supportive care study 2022. The publication is cited as Asgharzadeh Fereshteh, Tarnava Alex, Mostafapour Asma, Khazaei Majid, LeBaron Tyler W, World Journal of Gastrointestinal Oncology, 2022. This animal study examined Hydrogen-rich water exerts anti-tumor effects comparable to 5-fluorouracil in a colorectal cancer xenograft model. The abstract describes Mouse model; hydrogen delivered as hydrogen water. The abstract reports: Administration of HRW, with or without 5-FU, may serve as a therapeutic for treating CRC. This is an automated editorial draft based on the abstract and requires source review before publication.
Hydrogen water cancer supportive care study 2022 overview
To investigate the effects of HRW, with or without 5-FU, as a novel therapeutic for CRC. Animal research can identify biological effects and support future investigation, but it cannot by itself establish safety or effectiveness in humans.
Study design and hydrogen intervention
Publication type: Animal study. Evidence type: Preclinical animal evidence. Research model or population: Mouse model. Blinding: Unknown. Control status: Control group reported.
Delivery method: Hydrogen water.
Reported findings and scientific interpretation
For this hydrogen water cancer supportive care study 2022, the study record reports the following: The abstract reports: Administration of HRW, with or without 5-FU, may serve as a therapeutic for treating CRC.
These findings should be interpreted as one piece of evidence rather than as a stand-alone medical conclusion. Results can be influenced by the research model, study design, treatment protocol, sample size, outcome selection, statistical methods, and whether the findings have been independently reproduced.
How this research record was prepared
H2HUBB organizes bibliographic details, study design information, intervention data, outcomes, limitations, and safety notes from the available scientific source. Automated classification supports database organization, but it does not replace critical reading of the complete paper. Source identifiers, evidence labels, and delivery-method fields are retained so readers can verify the record and compare it with related publications. A missing field means the information was unavailable or not reported in the structured source; it should not be treated as a negative finding.
Limitations, safety, and original source
Limitations: Preclinical animal findings may not translate directly to human outcomes.
Safety: The abstract did not provide detailed safety or adverse-event information.
This H2HUBB page is an educational research record, not medical advice. Review the original scientific source for the complete methods and results. Continue exploring the H2HUBB Molecular Hydrogen Research Library to compare evidence types, delivery methods, and related topics.